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To find out more, go to www.simon-kucher.com Coming to a negotiated agreement for reimbursement in France, Italy, and Spain typically takes between 1 and 2 years, but there is no recognizable trend by market (see graph 1).
Few products get a national negotiated price within a year. The products EMA-approved in 2014 have yet to get a national negotiated price in either France, Italy or Spain.
Germany is the most consistent with regards to coming to a negotiated agreement. Manufacturers are able to freely set their prices for the first year before coming to a negotiated agreement with the GKV-SV on a discount. At the end of one year, a manufacturer will either have an agreement, be forced to go to arbitration, or have withdrawn from the market.
Even though in some markets manufacturers are able to be on the market for an initial period of time before coming to a negotiated agreement (e.g. in France, hospital drugs not on the T2A exclusion list do not have to negotiate their prices with CEPS or, in Italy, EMA approved drug can immediately be launched as Class C (nn) non-reimbursed drug with free pricing), uptake is likely to be slow until an agreement is nationally negotiated.
Introduction:
The keys to making authentic, Southern style, barbecued pulled pork are very simple. First, one must take their time and cook it very slowly. Second, the temperature must be kept really low so as not to dry out the meat. Lastly, the pork should be shredded to pull out the tastiest bits and discard any of the pieces you aren't interested in eating.
In surveying the current European pricing and access landscape for oncology products, one could argue that European payers have taken a page right out of a Southern BBQ cookbook with regards to their approach to reimbursing oncology therapies.
While this approach is working very well for EU payers, and BBQ lovers, one could argue that it has likely been giving oncology manufacturers indigestion.
Objectives:
Investigate market access delays caused by lengthy pricing and reimbursement negotiations in the EU4 (France, Italy, Spain and Germany).
Review results of those pricing negotiations compared to the US, and the outcome with regards to access for specific subpopulations.
Methods:
Examined over 20 oncology NMEs with EMA approval since 2011.
Collected the date of initial price publication in each market, HTA agency outcomes (where available), and price level at launch (France, Italy, Spain and Germany).
Evaluated the length of the price negotiation and compared price levels across EU markets as well as with the United States.
The research did not examine the UK as there is no national negotiating body.
Results: Lesson #3 -Prepare to have your trial shredded Some HTA agencies in Europe already request segmented data and may even analyze their own sub-groups of clinical trials to identify which patient populations derive the most benefit, and for which patient populations products have a lower value proposition.
This trend is especially true for Germany. In 13 out of 23 (56%) new oncology products having gone through a GBA assessment in the past 4 years, the GBA found no benefit to treating one or more of the patient populations (rating of 5 or 6).
On the other hand, this segmentation has an upside as most of these products also received a rating of 1-4 in at least one subgroup, allowing the manufacturer to move forward with the negotiation process.
In France, there are also a few examples of differential evaluation by subgroup such as Stivarga and Iclusig but this is not as common as in Germany (at least in oncology).
Conclusion
With slow negotiations, low price potential, and limited patient population, EU markets are not as rewarding for oncology manufacturers as they used to be.
Some argue that the style of Southern BBQ originated as a way to take low quality, inexpensive cuts of meat and transform them into something useful. While "low and slow" makes for fantastic shredded pork, it is not an exciting recipe for pharmaceutical and biotech manufacturers looking to market their products in Europe.
We are now seeing oncology medications that could easily be considered "me-toos" with similar MOAs and little incremental advancement over existing therapies entering the market. This explosion in oncology launches over the past years have left payers scrutinizing the added value of new products. We are seeing payers demonstrating little interest in making those drugs available to patients quickly or at an attractive price.
In this new reality, it will be critical for pharmaceutical manufacturers to develop realistic forecasts for new products, particularly those that are entering therapeutic areas with a substantial number of existing therapies. Armed with realistic expectations for the pricing and market access opportunities for these compounds, pharmaceutical and biotech manufacturers can then make the best possible decisions about where to invest their R&D spend.
Such a realignment from the "herd mentality" of everyone chasing the same therapeutic targets to a more high risk but high reward approach of looking for true innovation will hopefully lead to better patient outcomes, and higher profits for pharmaceutical and biotech manufacturers.
1-3 Additional benefit
4 Non-quantifiable benefit 5-6 No benefit Patients who have received at least one prior therapy, and for whom:
• chemotherapy is suitable -a chemotherapy or therapy with ofatumumab is suitable -a chemotherapy or therapy with ofatumumab is not suitable • Monotherapy follicular lymphoma (FL)refractory to two prior lines of treatment.
5
*Orphan Drug: orphan drug status will result in a "proven added benefit" vs. the clinical trial comparator (by law) Oncology pricing in the EU4 has been found to be significantly lower than the US WAC price at the time of first EU agreement by an average of 30-40% (exchange rate as of 1st EU agreement).
Looking at average EU4 prices in the last 4 years, only 2 oncology products (Imnovid andTafinlar) launched at higher prices in the EU than in the US.
The gap between average EU4 and US pricing continues to increase post-launch as prices increase in the US. Compared to current WAC (exchange rate as of 1st EU agreement) the price gap increases by 6-7%.
Note that this analysis only looks at published prices (incl. known discounts in Germany, Italy and Spain) but in most markets payers also negotiate risk-sharing agreements and additional confidential discounts bringing net prices even lower than reported.
Results: Lesson #2 -Oncology pricing in the EU is low, low, low 
